title: Telaprevir: clinical pharmacokinetics, pharmacodynamics, and drug-drug interactions.
abstract: This article provides an unbiased review of the pharmacokinetic, pharmacodynamic, and drug-drug interaction data of telaprevir, an NS3/4A protease inhibitor. Telaprevir is well absorbed with fatty food, moderately protein bound (59-76 %) with a large volume of distribution (~252 L), primarily metabolized by cytochrome P450 (CYP) 3A4 and P-glycoprotein, and is largely excreted into feces. Pharmacokinetic and pharmacodynamic parameters are well described in healthy subjects and individuals infected with hepatitis C virus (HCV), although only limited data are available in specific patient subpopulations. Telaprevir is recommended to be given at 750 mg by mouth every 8 h for 12 weeks, in combination with peginterferon and ribavirin (the standard care). The addition of telaprevir to the standard care regimen results in increased sustained virological response in treatment-naïve patients (30 %) and treatment-experienced patients (up to 50 %), and works synergistically to lower viral resistance. Telaprevir is a substrate and/or inhibitor of CYP3A4 and P-glycoprotein, and drug-drug interaction studies in humans have focused on these pathways. Based on our analysis, a few reported drug-drug interactions may be classified as clinically significant, but more experiments under dosing conditions that resemble those given in the clinic are needed to understand the relevance of some of the reported interactions. Future studies should focus on the pharmacokinetics/pharmacodynamics of telaprevir in special populations or patients with concomitant conditions that will likely co-exist with HCV infection, with an emphasis on establishing pharmacokinetic-pharmacodynamic relationships. In vitro characterization of other phase 1-3 metabolic pathways could assist in elucidating the mechanisms of the drug-drug interactions observed in humans.
authors.affiliation: Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada.
authors.forename: Tony K L
authors.initials: TK
authors.lastname: Kiang
authors.forename: Kyle J
authors.initials: KJ
authors.lastname: Wilby
authors.forename: Mary H H
authors.initials: MH
authors.lastname: Ensom
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004347:Drug Interactions; D006801:Humans; D009842:Oligopeptides / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011480:Protease Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; D011480:Protease Inhibitors; C486464:telaprevir
references.citation: Gastroenterology. 2006 Oct;131(4):997-1002
references.pmid: 17030169
references.citation: J Viral Hepat. 2012 Feb;19(2):e112-9
references.pmid: 22239508
references.citation: J Viral Hepat. 2011 May;18(5):305-15
references.pmid: 21470343
references.citation: Gastroenterology. 2006 Aug;131(2):478-84
references.pmid: 16890602
references.citation: Hepatology. 2006 Sep;44(3):521-6
references.pmid: 16941687
references.citation: N Engl J Med. 2009 Apr 30;360(18):1839-50
references.pmid: 19403903
references.citation: Hepatology. 2007 Sep;46(3):640-8
references.pmid: 17879366
references.citation: N Engl J Med. 2011 Jun 23;364(25):2417-28
references.pmid: 21696308
references.citation: Antivir Ther. 2012;17(7):1211-21
references.pmid: 22954756
references.citation: N Engl J Med. 2010 Apr 8;362(14):1292-303
references.pmid: 20375406
references.citation: Antivir Chem Chemother. 2007;18(3):163-7
references.pmid: 17626600
references.citation: Antimicrob Agents Chemother. 2006 Mar;50(3):899-909
references.pmid: 16495249
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: PLoS One. 2012;7(4):e34372
references.pmid: 22511937
references.citation: J Hepatol. 2008 Aug;49(2):163-9
references.pmid: 18486984
references.citation: Gastroenterology. 2007 May;132(5):1767-77
references.pmid: 17484874
references.citation: Aliment Pharmacol Ther. 2010 Aug;32(3):344-55
references.pmid: 20497143
references.citation: J Clin Pharmacol. 2014 May;54(5):563-73
references.pmid: 25975423
references.citation: Hepatology. 2011 Jul;54(1):20-7
references.pmid: 21618566
references.citation: PLoS Comput Biol. 2012 Jan;8(1):e1002339
references.pmid: 22241977
references.citation: Biochem Pharmacol. 2012 Oct 15;84(8):1096-102
references.pmid: 22902721
references.citation: N Engl J Med. 2011 Jun 23;364(25):2405-16
references.pmid: 21696307
references.citation: Antimicrob Agents Chemother. 2011 Oct;55(10):4569-74
references.pmid: 21825288
references.citation: J Clin Pharmacol. 2012 Oct;52(10):1566-73
references.pmid: 22162542
references.citation: N Engl J Med. 2009 Apr 30;360(18):1827-38
references.pmid: 19403902
references.citation: Hepatology. 1997 Sep;26(3 Suppl 1):122S-127S
references.pmid: 9305676
references.citation: Pharmacotherapy. 2011 Oct;31(10):951-74
references.pmid: 21950642
references.citation: Ann Pharmacother. 2007 Apr;41(4):674-80
references.pmid: 17389673
references.citation: Clin Pharmacokinet. 2007;46(4):281-90
references.pmid: 17375980
references.citation: Antimicrob Agents Chemother. 2006 May;50(5):1813-22
references.pmid: 16641454
references.citation: Br J Clin Pharmacol. 2013 Feb;75(2):431-9
references.pmid: 22642697
references.citation: Drug Metab Dispos. 2012 Sep;40(9):1698-711
references.pmid: 22648560
references.citation: Gastroenterology. 2006 Jan;130(1):231-64; quiz 214-7
references.pmid: 16401486
references.citation: Antimicrob Agents Chemother. 2012 Jul;56(7):3641-7
references.pmid: 22564847
references.citation: Ann Pharmacother. 2011 May;45(5):639-48
references.pmid: 21558488
references.citation: J Clin Pharmacol. 2012 Oct;52(10):1574-83
references.pmid: 22039291
references.citation: Gastroenterology. 2011 Feb;140(2):459-468.e1; quiz e14
references.pmid: 21034744
references.citation: N Engl J Med. 2011 Sep 15;365(11):1014-24
references.pmid: 21916639